Compare Novartis AG (NVS) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Schwab US Dividend Equity ETF — how do they compare? Novartis AG trades at $137.61 (market cap $262.64B), while Schwab US Dividend Equity ETF trades at $34.22. The key difference: Novartis AG pays a 3.44% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | SCHD | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $35.21 |
52-Week Low | $121.80 | $26.44 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
SCHD trades at $34.41, down 1.12% over the past day, with technical indicators showing a mixed but overall bullish bias. The ETF's recent dividend announcement for June 2026 highlights its income focus, while news coverage emphasizes its role in retirement portfolios and comparisons with peers like JEPI. Support and resistance levels are tightly clustered around $34-$35, indicating potential for near-term consolidation.
The outlook for SCHD remains favorable for dividend-focused investors, supported by strong inflows and media optimism, though risks include market volatility and competition from other income ETFs. Its low expense ratio and quality screening process continue to attract long-term holders seeking steady income and moderate growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
